IDEXX Laboratories/$IDXX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About IDEXX Laboratories
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
Ticker
$IDXX
Sector
Primary listing
Employees
11,000
Headquarters
Website
IDXX Metrics
BasicAdvanced
$51B
53.38
$12.01
1.50
-
Price and volume
Market cap
$51B
Beta
1.5
52-week high
$688.12
52-week low
$356.14
Average daily volume
600K
Financial strength
Current ratio
1.113
Quick ratio
0.677
Long term debt to equity
30.834
Total debt to equity
84.813
Interest coverage (TTM)
31.37%
Profitability
EBITDA (TTM)
1,454.332
Gross margin (TTM)
61.54%
Net profit margin (TTM)
24.41%
Operating margin (TTM)
31.09%
Effective tax rate (TTM)
19.72%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
23.26%
Return on equity (TTM)
64.87%
Valuation
Price to earnings (TTM)
53.377
Price to revenue (TTM)
12.936
Price to book
35.23
Price to tangible book (TTM)
35.23
Price to free cash flow (TTM)
67.454
Free cash flow yield (TTM)
1.48%
Free cash flow per share (TTM)
9.505
Growth
Revenue change (TTM)
6.68%
Earnings per share change (TTM)
19.17%
3-year revenue growth (CAGR)
6.86%
10-year revenue growth (CAGR)
10.18%
3-year earnings per share growth (CAGR)
15.83%
10-year earnings per share growth (CAGR)
20.45%
What the Analysts think about IDXX
Analyst ratings (Buy, Hold, Sell) for IDEXX Laboratories stock.
Bulls say / Bears say
In Q2 2025, IDEXX posted revenue of $1.11 billion, beating analysts’ estimate of $1.07 billion, and reported adjusted EPS of $3.63, above the $3.30 consensus.
The company installed almost 2,400 IDEXX inVue Dx units in the second quarter, raising its full-year placement outlook by 1,000 units to 5,500, underscoring strong demand for its point-of-care diagnostics device.
IDEXX raised its 2025 full-year EPS guidance to $12.40–$12.76 and its sales forecast to $4.21 billion–$4.28 billion, both above earlier ranges, citing strong global pet diagnostics demand and solid operational performance.
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
IDXX Financial Performance
Revenues and expenses
IDXX Earnings Performance
Company profitability
IDXX News
AllArticlesVideos
IDEXX Laboratories to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference
Business Wire2 weeks ago
S&P 500 Gains and Losses Today: Retail Sector Stocks Rise Amid Rate Cut Hopes
Investopedia1 month ago
Final Trades: Delta Air Lines, Tesla, Idexx Lab and the IYF
CNBC Television1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for IDEXX Laboratories stock?
IDEXX Laboratories (IDXX) has a market cap of $51B as of September 14, 2025.
What is the P/E ratio for IDEXX Laboratories stock?
The price to earnings (P/E) ratio for IDEXX Laboratories (IDXX) stock is 53.38 as of September 14, 2025.
Does IDEXX Laboratories stock pay dividends?
No, IDEXX Laboratories (IDXX) stock does not pay dividends to its shareholders as of September 14, 2025.
When is the next IDEXX Laboratories dividend payment date?
IDEXX Laboratories (IDXX) stock does not pay dividends to its shareholders.
What is the beta indicator for IDEXX Laboratories?
IDEXX Laboratories (IDXX) has a beta rating of 1.5. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.